Abstract:PURPOSE: While the beneficial effects of medications are numerous, drug-drug interactions may lead to adverse drug reactions that are preventable causes of morbidity and mortality. Our goal was to quantify the prevalence of potential drug-drug interactions in drug prescriptions at Danish hospitals, estimate the risk of adverse outcomes associated with discouraged drug combinations, and highlight the patient types (defined by the primary diagnosis of the admission) that appear to be more affected.METHODS: This cross-sectional (descriptive part) and cohort study (adverse outcomes part) used hospital electronic health records from two Danish regions (~2.5 million people) from January 2008 through June 2016. We included all inpatients receiving two or more medications during their admission and considered concomitant prescriptions of potentially interacting drugs as per the Danish Drug Interaction Database. We measured the prevalence of potential drug-drug interactions in general and discouraged drug pairs in particular during admissions and associations with adverse outcomes: post-discharge all-cause mortality rate, readmission rate and length-of-stay.RESULTS: Among 2 886 227 hospital admissions (945 475 patients; median age 62 years [IQR: 41-74]; 54% female; median number of drugs 7 [IQR: 4-11]), patients in 1 836 170 admissions were exposed to at least one potential drug-drug interaction (659 525 patients; median age 65 years [IQR: 49-77]; 54% female; median number of drugs 9 [IQR: 6-13]) and in 27 605 admissions to a discouraged drug pair (18 192 patients; median age 68 years [IQR: 58-77]; female 46%; median number of drugs 16 [IQR: 11-22]). Meropenem-valproic acid (HR: 1.5, 95% CI: 1.1-1.9), domperidone-fluconazole (HR: 2.5, 95% CI: 2.1-3.1), imipramine-terbinafine (HR: 3.8, 95% CI: 1.2-12), agomelatine-ciprofloxacin (HR: 2.6, 95% CI: 1.3-5.5), clarithromycin-quetiapine (HR: 1.7, 95% CI: 1.1-2.7) and piroxicam-warfarin (HR: 3.4, 95% CI: 1-11.4) were associated with elevated mortality. Confidence interval bounds of pairs associated with readmission were close to 1; length-of-stay results were inconclusive.CONCLUSIONS: Well-described potential drug-drug interactions are still missed and alerts at point of prescription may reduce the risk of harming patients; prescribing clinicians should be alert when using strong inhibitor/inducer drugs (i.e. clarithromycin, valproic acid, terbinafine) and prevalent anticoagulants (i.e. warfarin and non-steroidal anti-inflammatory drugs - NSAIDs) due to their great potential for dangerous interactions. The most prominent CYP isoenzyme involved in mortality and readmission rates was 3A4.

Investigation of polypharmacy, antimicrobial-related potential drug–drug interactions in patients with hematological malignancies

Assessment of potential drug–drug interactions in hospitalized cancer patients

Empirical polymyxin B therapy in febrile neutropenic patients with hematological diseases: A prospective, multicenter, observational clinical study

Assessment of polypharmacy, potentially inappropriate medications, and drug-drug interactions in older patients with cancer

Real-life drug–drug and herb–drug interactions in outpatients taking oral anticancer drugs: comparison with databases

Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients

Pharmacist's role in the management of drug–drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients

Determination of drug-related problems in the hematology service: a prospective interventional study

The evaluation of potential drug-drug interactions with antibiotics in hospitalized patients

Trends and Determinants of Polypharmacy and Potential Drug-Drug Interactions at Discharge From Hospital Between 2009–2015

Drug interactions in hospital prescriptions in Denmark: Prevalence and associations with adverse outcomes

Concordance analysis of two databases to search for potential drug interactions in onco-hematologic patients

Potential drug-drug interactions in outpatient lung cancer patients in a university hospital

Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs

Prevalence and comparative analysis of potential drug-drug interactions among hospitalized patients at a tertiary care cardiac institute in Pakistan: Findings from a single centre

Prevalence of polypharmacy and drug interaction among hospitalized patients: opportunities and responsabilities in pharmaceutical care

Identification of serious drug-drug interactions: Results of the partnership to prevent drug-drug interactions

Intrabases divergences in the mHealth era: a drug interaction investigation in an infectious-diseases hospital setting

Drug-Drug Interactions in Hospitalized Urological Patients: A Retrospective Cohort Study

Survey of Potential Drug Interactions, Use of Non-Medical Health Products, and Immunization Status among Patients Receiving Targeted Therapies

Assessment of potential drug-drug interactions at hospital discharge